UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) | |||
Registrant’s telephone number, including area code:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by a check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 – Other Events.
US Defense Logistics Agency Contract Award
On November 22, 2022, the US Defense Logistics Agency awarded OraSure Technologies, Inc. (the “Company”) a second procurement contract for the Company’s InteliSwab® COVID-19 Rapid Test for over-the-counter use. Under the terms of the award, the contract estimate is 18 million InteliSwab® COVID-19 Rapid Tests; with a maximum award of 36 million tests and a guaranteed minimum award of 3.6 million tests. The contract will run from November 2022 through November 2023. Due to lack of visibility of order timing, the Company is not updating its financial guidance for the fourth quarter of 2022 at this time. Pricing for the InteliSwab® COVID-19 Rapid Test, under this contract, is below what was previously awarded by the federal government.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ORASURE TECHNOLOGIES, INC. | ||||||
| Date: November 22, 2022 |
By: | /s/ Carrie Eglinton Manner | ||||
| Carrie Eglinton Manner | ||||||
| President and Chief Executive Officer | ||||||
3
Document and Entity Information |
Nov. 22, 2022 |
|---|---|
| Cover [Abstract] | |
| Entity Registrant Name | ORASURE TECHNOLOGIES INC |
| Amendment Flag | false |
| Entity Central Index Key | 0001116463 |
| Document Type | 8-K |
| Document Period End Date | Nov. 22, 2022 |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-16537 |
| Entity Tax Identification Number | 36-4370966 |
| Entity Address, Address Line One | 220 East First Street |
| Entity Address, City or Town | Bethlehem |
| Entity Address, State or Province | PA |
| Entity Address, Postal Zip Code | 18015-1360 |
| City Area Code | 610 |
| Local Phone Number | 882-1820 |
| Security 12b Title | Common Stock, $0.000001 par value per share |
| Trading Symbol | OSUR |
| Security Exchange Name | NASDAQ |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Entity Emerging Growth Company | false |
-8?20$3;8T.P6BP^0"X99K>]9!:G